MDCalc

Myelofibrosis Secondary to Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Prognostic Model

Predicts survival in post-PV and post-ET patients with secondary myelofibrosis.

years

Hemoglobin

Platelets

Circulating blast cells

CALR-unmutated genotype

Constitutional symptoms

Fever, weight loss, night sweats

Result:

Please fill out required fields.
Advice
  • Use risk categories and median survival estimates to tailor management plans and guide goals-of-care discussions with patients.
  • Patients within intermediate-2 and high risk categories, particularly younger individuals with good functional status, may benefit from allogeneic stem cell transplantation.
  • Low-risk individuals may be suited for a more conservative treatment approach.
  • Do not base management decisions solely on these results; integrate them with clinical judgment, specialist consultations, and patient preferences.